Actively Recruiting
Treatment of Enterococcus Faecalis Bacterem
Led by University Hospital, Strasbourg, France · Updated on 2025-12-23
700
Participants Needed
1
Research Sites
92 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Enterococcus faecalis is a germ frequently responsible for bacteremia which can be severe with 15-25% risk of mortality and 26% risk of infectious endocarditis. There is no recommendation for the treatment of "simple" Enterococcus faecalis bacteremia (meaning without infectious endocarditis at diagnosis), nor studies comparing monotherapy versus combination antibiotic therapy. Our main objective is to study the impact on mortality of bacteriostatic monotherapy and bactericidal combination antibiotic therapy in patients with Enterococcus faecalis bacteremia. We aim to also study the mortality up to three months, the failures of treatment, the modalities of treatment, the renal toxicity and the bacterial resistance.
CONDITIONS
Official Title
Treatment of Enterococcus Faecalis Bacterem
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Subject of legal age (6518 years)
- Positive blood culture result for Enterococcus faecalis from the University Hospital of Strasbourg between 01 January 2017 and 31 December 2023
You will not qualify if you...
- Penicillin treatment less than 7 days
- Treatment not including an effective penicillin (amoxicillin or piperacillin-tazobactam) against enterococci
- Combination of penicillin with other antibiotics effective against enterococci aside from cephalosporins or aminoglycosides
- Bacteremia with other pathogens within the first 7 days
- Infective endocarditis at diagnosis or within the first 7 days of treatment
- Resistance of Enterococcus faecalis to amoxicillin
- Death within 72 hours after starting antibiotic therapy
- Missing information on the chosen antibiotic treatment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Service des Maladies Infectieuses et Tropicales - CHU de Strasbourg - France
Strasbourg, France, 67091
Actively Recruiting
Research Team
Y
Yvon RUCH, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here